Electrophysiological disturbances in heart failure

R W F Campbell

Cardiac arrhythmias are a frequent and important complication of cardiac failure regardless of aetiology. It might be expected that those afflicted would be aware of their occurrence, but surprisingly, even salvos of ventricular tachycardia often are not perceived by patients. It has required 24 hour ambulatory electrocardiographic recordings to disclose the true prevalence of arrhythmias.

The typical arrhythmias complicating heart failure comprise atrial and ventricular extrasystoles, atrial fibrillation (which is arguably the most important arrhythmia), and short paroxysms of polymorphic ventricular tachycardia. Sustained regular QRS tachycardias and monomorphic ventricular tachycardia are unusual. This spectrum of arrhythmias suggests that either triggered automaticity or complex functional re-entry are the more usual basic electrophysiological arrhythmogenic mechanisms in heart failure than is single circuit re-entry.

Prognostic importance of arrhythmias in heart failure

In many cardiovascular diseases, the impact of complicating arrhythmias extends beyond that of their symptomatic upset. A variety of ventricular arrhythmias are of prognostic importance in patients after a myocardial infarction, and in those with aortic stenosis or hypertrophic cardiomyopathy. Ventricular arrhythmias are also of prognostic importance in heart failure. Patients with high frequency ventricular extrasystoles fare more poorly than those with low frequency extrasystoles. The association, not surprisingly, raised the possibility that many patients with heart failure who died did so because of ventricular tachycardias. There is still great controversy surrounding this concept. It is certainly true that even in patients with heart failure, sudden unexpected and presumptively arrhythmic death occurs with surprising frequency. But in studies following up individual patients, although ventricular arrhythmias were common, and mortality high, mortality attributable to ventricular tachycardias was rare.

Treatment of arrhythmias in heart failure

Treatment of arrhythmias in patients with heart failure is difficult. Most arrhythmias might be expected to have particularly serious consequences in those with impaired cardiac function and so merit enthusiastic suppression, but most available antiarrhythmic drugs depress left ventricular performance and are either relatively or absolutely contraindicated. In general, treatment is appropriate for only those arrhythmias, such as atrial fibrillation, which cause haemodynamic upset.

Antiarrhythmic drugs may be indicated in individual patients for the control of specific arrhythmias, but attempts to improve prognosis in heart failure by suppressing ventricular arrhythmias with antiarrhythmic treatment have been most disappointing. Middlekauff et al in a non-randomised observational study found one year survival rates of 76% in patients taking class I antiarrhythmic treatment v 86% for those receiving no antiarrhythmic treatment. Perhaps it is not surprising that class I antiarrhythmic drugs produced no benefit but it has been widely believed that amiodarone would prove to be an important intervention. Although the situation is far from proved, current evidence is not encouraging. Stewart et al in a placebo controlled randomised study showed no benefits of amiodarone treatment in a one year follow up of patients with heart failure and complicating ventricular arrhythmias. The Basel antiarrhythmic study of infarct survival was conducted in patients after an infarct and examined amiodarone v conventional treatment v no antiarrhythmic drug treatment in survivors of an acute myocardial infarction. A significant benefit of amiodarone was shown. This finding was echoed by the Polish amiodarone study. In both studies a proportion of the enrolled patients had heart failure and it might be inferred that in this context of impaired left ventricular dysfunction, amiodarone might have benefits. A recent analysis of the BASIS study suggests not. Pfisterer and colleagues showed that in the BASIS study prognostic benefits from amiodarone accrued to those with ejection fractions (EFs) >40% but in those with impaired left ventricular function (EF <40%) amiodarone showed no benefits by comparison with control treatment.

What lessons can we derive from these therapeutic findings in relation to the mechanisms of arrhythmias in heart failure? It would seem that in heart failure as with many other cardiac conditions, prognostically important cardiac arrhythmias are markers of risk rather than direct mechanisms of death. The failure of antiarrhythmic drugs to prevent mortality must mean either that death in patients with heart failure is not arrhythmically mediated, which is in keeping with some
suggestions, or else that currently available antiarrhythmic options are ineffective against fatal arrhythmic events. If this were true, it might suggest that the fundamental mechanism of arrhythmias in heart failure is different from that of the marker events as the marker events are suppressible.

Electrophysiological abnormalities of heart failure
Heart failure is not a specific disease. In that it is a syndrome complex secondary to a variety of cardiovascular diseases, these primary pathological events may in themselves create arrhythmias. When heart failure develops, a complex range of important and potentially arrhythmogenic phenomena occur. They include increased circulating catecholamines, electrolytic disturbances, and myocardial hypertrophy. Also, in most processes causing heart failure, fibrous tissue replaces functioning myocardium. The fibrosis may be relatively confluent as in myocardial infarction, be patchy as in the mottled infarct patterns of microembolic infarction, or may be dramatically inconsistent resembling that seen in hypertrophic cardiomyopathy.

There is no specific electrophysiological signature of heart failure. Rather the electrophysiological abnormalities reflect the varying contributions both of the processes of damage and repair and of the reflex responses to the condition.

CATECHOLAMINES
Part of the neurohormonal response to heart failure is an increase in circulating catecholamines that might, as in other cardiovascular pathological events, be expected to have an arrhythmogenic effect. Certainly the prognosis of heart failure is intimately linked with circulating plasma noradrenaline concentrations, but myocardial \( \beta \) receptors are down regulated in the face of constant high circulating catecholamine concentrations. This might be interpreted as providing relative myocardial protection, but this is not proved and might in any case depend on the uniformity of expression of the remaining \( \beta \) receptors.

ELECTROLYTES
Electrolytic derangements, principally those of potassium and magnesium, are common in heart failure either because of the basic disease process causing heart failure or more commonly, as a consequence of the treatment of heart failure with diuretics that cause loss of electrolytes. Low potassium concentrations may encourage triggered automatic behaviour but the effect of a low magnesium concentration is more controversial; it correlates with age and severity of heart failure but not with sudden death.

VENTRICULAR HYPERTROPHY
Hypertrophy is increasingly recognised as an important component of the reflex changes associated with heart failure. Although it offers some mechanical advantages principally related to energy conservation, hypertrophy has been identified as an important adverse prognostic risk factor. Transventricular conduction times are slowed in the hypertrophied heart although conduction velocity is not necessarily impaired. In extreme cases, ventricular hypertrophy may outstrip available oxygen supply producing areas of focal ischaemia and thus creating electrical inhomogeneity.

MYOCARDIAL STRETCH
Excitation contraction feedback is receiving considerable attention. When myocardial cells are stretched their membrane potentials may become unstable and create triggered automatic arrhythmias.

FIBROSIS
The implications of fibrosis in the myocardium are only now receiving attention. In hypertrophic cardiomyopathy, important changes in latency and cell to cell coupling have been shown, and these may eventually be correlated with prognosis. Fibrosis interferes with cell to cell transmission of the depolarising wave front.

GAP JUNCTIONS
There is evidence that in heart failure gap junctions may be deficient so interfering with cell to cell electrical transmission.

Mechanisms of arrhythmias in heart failure
Single circuit re-entry is a most uncommon mechanism of arrhythmias in patients with heart failure unless it is generated by the disease responsible for the heart failure. Single circuit re-entry is typified by the sustained monomorphic ventricular tachycardia that complicates the late period after infarction and by the reciprocating tachycardia of Wolff-Parkinson-White syndrome. Most arrhythmias in heart failure are probably based on either interlacing wavelets of re-entry or triggered automaticity.

INTERLACING WAVELETS OF RE-ENTRY
Atrial fibrillation is probably the commonest arrhythmic complication of heart failure. Its basic mechanism has been postulated as interlacing wavelets of re-entry, a hypothesis that has been largely borne out by modern multipoint activation studies. Present day knowledge, supported by recent developments in the surgical management of atrial fibrillation, suggests that atrial fibrillation may not be a completely random process and further, that a relatively stable moderate number of circuits (6–10) may be responsible for the surface electrocardiogram. Based on the concept of wavelength, the emergence of atrial fibrillation may arise from reduced conduction velocity in the atrial myocardium allowing relatively small and multiple activation loops to be created within its available anatomy. Further, triggered automatic atrial extrasystoles may be a mechanism of creating electrical
Electrophysiological disturbances in heart failure

inhomogeneity in the atria, establishing a self perpetuating phenomenon manifest as the clinical arrhythmia.

TRIGGERED AUTOMATICITY
Triggered automaticity has been recognised as an experimental mechanism for arrhythmia but, with the possible exception of digitalis intoxication, no clinical arrhythmias had been shown to be due to this mechanism. Now there is growing belief that torsade de pointes is a triggered automatic arrhythmia.32 Furthermore, the typical ventricular tachycardias that complicate heart failure are relatively brief, irregular, polymorphic arrhythmias. They crudely share some of the characteristics of torsade de pointes and seem likely to be due to triggered automatic activity.

Therapeutic implications of mechanisms of arrhythmia for clinical management
In the early stages of heart failure both the atrial and ventricular myocardium have relatively normal electrophysiological properties and have not yet undergone permanent damage. As heart failure becomes chronic, stretch, hypertrophy, and the activation of several deleterious neuroendocrine responses including increases of circulating noradrenaline bring into play a variety of arrhythmogenic factors that may be difficult or impossible to reverse. There is thus a strong case for early intervention in heart failure in an attempt to prevent these responses. Arrhythmogenic manifestations in heart failure caused by electrolytic disturbances are readily amenable to management. Patients with heart failure are at serious risk of arrhythmias and scrupulous attention must be paid to preserving normal concentrations of electrolytes.

Remarkably little is understood about the benefits and detriments of increased concentrations of circulating noradrenaline in patients with heart failure. There is continuing research interest in the value of β blockers prescribed to highly selected patients, and several studies have shown that for at least some, impressive benefits can be provided.33,34 This is of great interest particularly as β blockers are one of the few interventions shown to improve prognosis for any cardiovascular disease, and their contribution in patients after a myocardial infarction is now well established. Moreover, in patients after a myocardial infarction retrospective analysis suggests that those patients with impaired left ventricular function may be those most likely to gain prognostic benefit.35 β Blockers are powerful antiarrhythmic drugs but their potentially deleterious effects in patients with heart failure brought about by their ability to block what may be a vital sympathetic drive demands that they be used with caution.36 Myocardial stretch encourages triggered automatic behaviour and it may be one of the stimuli for fibrosis. Stretch may also be involved in the altered function or disappearance of gap junctions. Myocardial stretch is most efficiently reduced by vasodilator treatment. Angiotensin converting enzyme (ACE) inhibitors have shown their ability to improve prognosis for patients with severe heart failure37 and for patients with moderate heart failure,38 and have also shown benefits for those with asymptomatic left ventricular dysfunction.39 They have been shown to reduce ventricular extrasystolic activity,40,41 and it was initially widely believed that ACE inhibitors might improve prognosis through protection from lethal arrhythmias. In the first prospective north Scandinavian enalapril survival study (CONSENSUS I) mortality was reduced but there was no evidence that this was due to an antiarrhythmic effect of the ACE inhibitors.39 Indeed, there is only one study, the second Veterans Administration heart failure trial (V-HeFT II), which has shown a reduction of sudden, presumptively arrhythmic, death associated with ACE inhibitor treatment.42 Interestingly in that study, the effect was shown, not v placebo, but v patients treated with the combination of isosorbide dinitrate and hydralazine. Thus if this result is confirmed in other studies, it would suggest that vasodilatation alone is insufficient to produce an antiarrhythmic effect and that it needs the special properties of an ACE inhibitor as opposed to those of more general vasodilatation produced by isosorbide dinitrate and hydralazine. None the less, small studies have suggested that other vasodilators may modify arrhythmias.43,44

Contribution of specific diseases
Diagnostic precision is increasing in patients presenting with heart failure. Although in a reasonable proportion an underlying disease can be identified, there is still an embarrassing number labelled as idiopathic dilated cardiomyopathy. As more is understood of the agents and infective particles able to inflict damage on the myocardium, a greater proportion of specific diagnoses will be made. There may be specific patterns of arrhythmia related to particular aetiologies of heart failure. There have been suggestions that the arrhythmias that complicate Chagas' disease are unique,45 and there is evidence that the electrophysiology of alcohol related heart muscle disease may be specific.46 In conclusion, every conceivable electrophysiological upset can occur in heart failure; there is no specific electrophysiological pattern associated with the syndrome. None the less, the process of arrhythmogenesis and heart failure has become easier to understand with growing recognition of triggered automatic arrhythmogenesis and the conditions necessary for interlaced wavelets of re-entry. Management strategies are turning from conventional drugs such as the class I antiarrhythmic agents to interventions that alter the underlying conditions of the myocardium, principally the ACE inhibitors, or which alter neurohormonal responses, principally the β blockers. Management also needs to be instituted early, much earlier than has been the
case in the past, if the electrophysiological changes that cause irreparable damage are to be identified. Such dramatic changes in clinical practice will introduce new risks and problems but at present they offer a new hope for quality of life. The field is exciting but there are large gaps in our knowledge.

Clinical electrophysiological studies, despite their complexity, show remarkably little of what is happening in the myocardium at a cellular level. Complex invasive investigations are inappropriate for patients either in the early stages of heart failure or for those who are severely incapacitated. Much of our understanding of the abnormalities in the electrophysiology of heart failure comes either from clinical deductions in the light of clinical electrophysiological experience or from experimental studies. Perhaps most difficult of all is to acknowledge that the electrophysiological milieu in heart failure is not static. It may change in a remarkably short time. Were the electrophysiology of the failing heart to be characterised at one point in time then it is conceivable that a relatively untoward event could turn a stable but abnormal situation into one that is suddenly fatal. An unexpected crisis that altered catecholamine concentrations or myocardial loading might be tolerated in the normal heart but in the failing heart could be the trigger for lethal arrhythmogene-


18 Wexler PO. Electrolyte balance in heart failure and the role for magnesium ions. Am J Cardiol 1972;70:44C-49C.


39 Webster MW, Fitzpatrick MA, Nichols MG, Bram H,
Electrophysiological disturbances in heart failure


